After a median follow-up of 2.3 years, methotrexate did not reduce levels of IL6, IL1beta, and CRP, nor did it decrease the incidence of the primary endpoint of cardiovascular death, myocardial infarction, or stroke. The gene discussed is IL1B; the disease is myocardial infarction.